Also trades as: 0JDK.L (LSE) · $vol 3M
IOVA NASDAQ
Iovance Biotherapeutics, Inc.
1W: -1.9%
1M: +32.7%
3M: +219.7%
YTD: +478.6%
1Y: +548.0%
3Y: +337.8%
5Y: -44.4%
$14.58
+0.80 (+5.81%)
Pre-Market: $14.54 (-0.04, -0.24%)
Weekly Expected Move ±18.3%
$9
$12
$14
$17
$19
Credit Risk of going bust: lower than 52% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.60B.
Distance to default 5.33 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.4%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.60B.
Distance to default 5.33 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.4%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.72
Bullish
4 bullish
1 neutral
0 bearish
Articles (24h)
5
Hourly Sentiment (24h)
Articles (5)
0.75
Bullish
5 bullish
1 neutral
0 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Best Momentum Stocks to Buy for October 27th
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
How to Find Strong Buy Medical Stocks Using the Zacks Rank
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
New Strong Buy Stocks for October 27th
Iovance sees long-term response for Amtagvi in first-line melanoma
Defensive rotation: Quality over sector labels in healthcare, banks, and consumer staples
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
30 U.S. stocks flashing Strong Buy ratings as earnings roll in
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
How yield surges hit small caps—and why BofA prefers mid caps
55,275 Shares of Iovance Biotherapeutics, Inc. $IOVA Purchased by Corient Private Wealth LP
What's next for personalized mRNA cancer vaccines?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance hits highest since 2024 as analysts cheer guidance raise
High-Stakes October has these Biotechs Entering Crucial Stretch
These ten healthcare stocks posted the biggest September gains
Iovance rises as 2026 revenue outlook tops analyst consensus
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Why Iovance Biotherapeutics Stock Was on Fire Today
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Iovance Biotherapeutics, Inc. $IOVA Shares Purchased by Tidal Investments LLC
WINTON GROUP Ltd Sells 291,457 Shares of Iovance Biotherapeutics, Inc. $IOVA
4 Biotech Stocks to Watch as Potential Takeover Targets
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Squarepoint Ops LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA
108,050 Shares in Iovance Biotherapeutics, Inc. $IOVA Bought by VIRGINIA RETIREMENT SYSTEMS ET Al
Jupiter Topco LLC Invests $589,000 in Iovance Biotherapeutics, Inc. $IOVA
Legal & General Group Plc Buys Shares of 259,485 Iovance Biotherapeutics, Inc. $IOVA
Bank of New York Mellon Corp Buys Shares of 1,162,097 Iovance Biotherapeutics, Inc. $IOVA
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
The best Quant-rated stocks trading below $10 right now
Most shorted stocks on Wall Street
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now
Biotech Breakout: What's in focus after Moderna's cancer win?
SA Asks: What are the most promising oncology companies right now?
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy
IOVA Stock Climbs As Amtagvi Sales Crush Q2 Expectations - timothysykes.com
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 11% Following Analyst Upgrade - MarketBeat
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus - simplywall.st
Rice Hall James & Associates LLC Acquires Shares of 1,539,840 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance
Iovance (IOVA) Q2 2026 Earnings Call Transcript
Iovance (IOVA) Q2 2026 Earnings Call Transcript
IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast - 24/7 Wall St.
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns - simplywall.st
Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains - simplywall.st
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next
Iovance Biotherapeutics Q2 Earnings Call Highlights
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2
Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Why Iovance Biotherapeutics (IOVA) Stock Is Up Today - Quiver Quantitative
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2 - Yahoo Finance
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts - ts2.tech
Iovance Biotherapeutics (IOVA) Following The Pullback Looks Cheap If The Bull Case Holds - simplywall.st
Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key - Yahoo Finance
Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key
Iovance Biotherapeutics (IOVA) Stock Looks Cheap On Sales While Returns Stay Weak - simplywall.st
Do Mixed Q2 Expectations Alter Iovance Biotherapeutics' (IOVA) TIL Leadership Narrative?
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus - Yahoo Finance
Neurocrine Biosciences Q2 Earnings Call Highlights
IOVA Stock Slides As Biotech Traders Watch Key Support - StocksToTrade
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
Iovance Sets Aug. 6 Webcast to Discuss Second-Quarter Results - Stock Titan
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 - Yahoo Finance
BlackRock (IOVA holder) reports 33.4M Iovance Biotherapeutics shares, a 7.5% stake - Stock Titan
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits